Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00469
|
|||||
| Drug Name |
Carboplatin
|
|||||
| Synonyms |
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II); Azanide; C 2538; Carbopaltin; Carboplatin (JAN/USP/INN); Carboplatin (USAN); Carboplatin [USAN:INN:BAN:JAN]; Carboplatine; Carboplatine [French]; Carboplatino; Carboplatino [Spanish]; Carboplatinum; Carboplatinum [Latin]; Cbdca; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(cyclobutanedicarboxylato)platinumII; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Diammine-1,1-cyclobutane dicarboxylate platinum II; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Ercar; IUPAC: Azane; JM 8; JM-8; Paraplatin; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Platinum(+2) Cation; Platinum(2+); Platinum(II), (1, 1-cyclobutanedicar; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); Platinum, {diammine[1,1-cyclobut
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Ovarian cancer [ICD11:2C73] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C6H12N2O4Pt
|
|||||
| Canonical SMILES |
C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]
|
|||||
| InChI |
InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2
|
|||||
| InChIKey |
OLESAACUTLOWQZ-UHFFFAOYSA-L
|
|||||
| CAS Number |
CAS 41575-94-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 371.25 | Topological Polar Surface Area | 82.3 | ||
| Heavy Atom Count | 13 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| PubChem CID | ||||||
| PubChem SID |
117682520
,127293893
,127293894
,127293895
,127293896
,127293897
,127293898
,127293899
,127293900
,127293901
,127293902
,127293903
,127293904
,127293905
,127293906
,127293907
,127293908
,127293909
,127293910
,127293911
,127293912
,127293913
,127293914
,127293915
,127293916
,127293917
,127293918
,127293919
,127293920
,127293921
,127293922
,127293923
,127293924
,127293925
,127293926
,127293927
,127293928
,127293929
,127293930
,127293931
,127293932
,127293933
,127293934
,127293935
,127293936
,15350457
,22704376
,33972238
,75354552
,87558792
|
|||||
| ChEBI ID |
ChEBI:31355
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CTR1 | Transporter Info | High affinity copper uptake protein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Carboplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.